New hope for brain cancer patients in major trial
NCT ID NCT07215910
Summary
This study is testing if adding a new targeted drug, vorasidenib, to the usual treatment (radiation and chemotherapy) works better for people with a specific type of newly diagnosed brain tumor called grade 3 astrocytoma. About 408 participants will receive either the new drug combination or a placebo with standard care to see which group has better long-term control of the cancer. The main goal is to see if the new combination can delay the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.